Title: Spin-off companies

Spin-off companies from the IRC

Three spin-off companies were created over the past years on the basis of previous research in the IRC.

ActoGeniX (created in 2006) ActoGeniX logo

ActoGeniX exploits the proprietary TopAct™ platform for oral delivery of biopharmaceuticals. The company is developing a diverse portfolio of therapeutic products addressing major diseases with a high medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic disease. ActoGeniX’ initial focus is on gastrointestinal diseases and its lead product has already been successfully tested in a clinical trial with Crohn’s Disease patients.

Based on technology developed in the IRC for the use of Lactococcus lactis as a vehicle for therapeutical protein delivery in the gut.

Oxyrane Belgium (created in 2008) Oxyrane logo

Oxyrane Belgium  ...(to be completed)

Q-Biologicals (created in 2011) 

Q-Biologicals  ...(to be completed)

Go back to the regular design...